AI Drug Discovery Startup Raises $400M
AAAzzam · x · 2026-07-14
A post shares funding news for an AI drug discovery company: it has closed a $400 million Series C round led by Index Ventures, with participation from Kleiner Perkins, Sequoia, DimensionCap, and others.
The concurrent business signal is that the value of AI in drug discovery has shifted from "proof of concept" to "actual deployment." The original post emphasizes that this is no longer just a discussion of future visions, but a transition into the execution phase.
Related event: AI Drug Discovery Firm Chai Raises $400M(3 posts)→
More from Venture
- Steal this idea: prompt-to-hardware where agents assemble custom devices — paraschopra · 2026-09-11
- Marc Loou gives away free book on making $3M from 36 startups, 90% of them failures — marclou · 2026-09-11
- Trucking brokerage acquired for its AI platform and 8,000-carrier network, not revenue — MatthewChang · 2026-09-11
- Investor argues Palantir-Nvidia partnership should slash Anthropic's IPO valuation — pdamodaran · 2026-09-11
- Moonshot's annualized revenue jumped from $300M to $1B in two months after Kimi K3 — Hesamation · 2026-09-11
- Mid-market companies' AI SEO bottleneck is ops execution, not strategy, says SEO practitioner — gaganghotra_ · 2026-09-11